These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12529183)

  • 1. Frequency of CHEK2*1100delC in New York breast cancer cases and controls.
    Offit K; Pierce H; Kirchhoff T; Kolachana P; Rapaport B; Gregersen P; Johnson S; Yossepowitch O; Huang H; Satagopan J; Robson M; Scheuer L; Nafa K; Ellis N
    BMC Med Genet; 2003 Jan; 4():1. PubMed ID: 12529183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
    Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
    Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
    Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
    Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
    Hallamies S; Pelttari LM; Poikonen-Saksela P; Jekunen A; Jukkola-Vuorinen A; Auvinen P; Blomqvist C; Aittomäki K; Mattson J; Nevanlinna H
    BMC Cancer; 2017 Sep; 17(1):620. PubMed ID: 28874143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.
    Apostolou P; Fostira F; Papamentzelopoulou M; Michelli M; Panopoulos C; Fountzilas G; Konstantopoulou I; Voutsinas GE; Yannoukakos D
    Cancer Genet; 2015 Apr; 208(4):129-34. PubMed ID: 25835597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
    Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
    Kleibl Z; Novotny J; Bezdickova D; Malik R; Kleiblova P; Foretova L; Petruzelka L; Ilencikova D; Cinek P; Pohlreich P
    Breast Cancer Res Treat; 2005 Mar; 90(2):165-7. PubMed ID: 15803363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.
    Bernstein JL; Teraoka SN; John EM; Andrulis IL; Knight JA; Lapinski R; Olson ER; Wolitzer AL; Seminara D; Whittemore AS; Concannon P
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):348-52. PubMed ID: 16492927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.
    Zhang S; Phelan CM; Zhang P; Rousseau F; Ghadirian P; Robidoux A; Foulkes W; Hamel N; McCready D; Trudeau M; Lynch H; Horsman D; De Matsuda ML; Aziz Z; Gomes M; Costa MM; Liede A; Poll A; Sun P; Narod SA
    Cancer Res; 2008 Apr; 68(7):2154-7. PubMed ID: 18381420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
    Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
    Chen W; Yurong S; Liansheng N
    Adv Ther; 2008 May; 25(5):496-501. PubMed ID: 18484200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
    Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
    Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
    Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
    Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
    Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
    Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.